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Abstract: 
Ranitidine Hydrochloride has a very bitter taste. The bitter taste of the drug makes administration of the dosage 
form difficult, especially to paediatric patients. Oral medicated jellies are novel drug delivery systems overcoming 
these problems. They are sucrose based formulation thus providing higher compliance. These formulations are also 
advantageous for geriatric and dysphagic patents. Natural polymers used in jelly formulation are biodegradable, 
biocompatible, nontoxic, low cost and environment friendly, locally available, better patient tolerated and edible. 
The aim was to develop and evaluate oral jelly formulations of Ranitidine Hydrochloride. Preformulation studies, 
organoleptic, physical characteristics, drug content, pH, syneresis, taste masking and in vitro dissolution testing 
were conducted. The Fourier transform infrared and differential scanning calorimeter studies showed that there 
was no interaction between drug and excipients. The concentration of gelling agents influenced the spreadability.  
The formulation F4 showing good pourabilty and gelling property so it was selected for further optimization by 
varying the degrees brix (⁰Brix). The pH of all the formulations was found between pH 5 to 6. The optimized 
formulations (F4.3) masked the bitter taste of Ranitidine Hydrochloride and demonstrated acceptable physical 
properties with 50% drug release in 15 min. The formulation was tested for microbial growth and was found to be 
stable.  
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INTRODUCTION: 
Peptic ulcers may be defined as discontinuities of the 
gastric or duodenal mucosa with penetration to the 
muscularis mucosae and exposure of the submucosa 
[1]. The integrity of the upper gastrointestinal tract is 
balanced between “hostile” factors such as gastric 
acid, H. pylori, NSAIDs and pepsin, and “protective” 
factors such as mucus, bicarbonate, prostaglandins 
and blood flow to mucosa affecting gastrointestinal 
mucosa. Imbalance in these factors affects the gastric 
mucosa giving rise conditions like peptic ulcer [2]. 
There are a number of factors which lead to ulcer 
formation. Secondary ulcers, on the contrary, are 
caused by extragastric pathogenic events, like, stress 
or drugs. Cushing ulcers are associated with a brain 
tumor or injury. Ulcers also develop as secondary 
conditions to various diseases. Hypersecretory states 
like multiple endocrine neoplasia type I (MEN-I), 
antral G-cell hyperplasia, systemic mastocytosis, 
gastrinoma (Zollinger-Ellison syndrome),  basophilic 
leukemias, cystic fibrosis, short bowel syndrome, and 
hyperparathyroidism may also lead to ulcerogenic 
state. Among all the causes use of use NSAID’s and 
H.pylori are the most prevalent [3].   
 NSAID’s reduce the hydrophobicity of gastric 
mucus this causes injury to surface epithelium by 
endogenous gastric acid and pepsin secreted. They 
inhibit cyclo- oxygenase -1 and cyclo- oxygenase -2. 
The anti-inflammatory properties of NSAIDs are 
mediated through inhibition of cyclo-oxgenase-2, and 
adverse effects of NSAID’s such as gastric and 
duodenal ulceration, occur mainly due effects on the 
constitutively expressed cyclo-oxygenase-1 [4,5]. 
The H. pylori infected individuals have increased 
resting and meal-stimulated gastrin levels and 
decreased gastric mucus production and duodenal 
mucosal bicarbonate secretion, all of which favor 
ulcer formation [6,7].  
Treatment of peptic ulcers includes use of antacids; 
H2 antagonist and proton pump inhibitors. H2 
antagonist. H2 antagonist [8, 9]. Ranitidine 
Hydrochloride is a histamine H2-receptor antagonist. 
It is widely prescribed in various conditions like 
gastric ulcers, duodenal ulcers, Zollinger-Ellison 
syndrome and gastroesophageal reflux disease [10]. 
Ranitidine HCl acts as competitive inhibitors of 
histamine at the parietal cell H2 receptor. It 
suppresses the normal secretion of acid by parietal 
cells and the meal-stimulated secretion of acid [11]. 
Ranitidine has a very bitter taste which makes 
administration of its formulation non-compliant, 
especially to paediatric patients. Oral medicated 
jellies are novel drug delivery systems overcoming 
these problems [12]. They are sucrose based 
formulation thus providing higher compliance. These 
formulations are also advantageous for geriatric and  
dysphagic patents. Natural polymers used in jelly 
formulation are biodegradable, biocompatible, 
nontoxic, low cost and environment friendly, locally 
available, better patient tolerated and edible [13]. 
Taste masking of Ranitidine HCl is mainly by 
addition of sweeteners and flavours and entrapment 
of the drug in the gelling matrix[14]. Hence the 
present study was directed towards formulating oral 
medicated jellies for Ranitidine HCl using pectin as 
the polymer. 
 
MATERIAL AND METHODS: 
Ranitidine was gift sample from Orchev Pharma, 
Gujrat. Pectin was obtained from Brenntag, India. 
Citric acid, Tri sodium citrate and sodium benzoate 
were purchased from Vikas Pharma, Mumbai. 
Dextrose and sucrose were purchased from Loba 
Chemie. Mango flavor was obtained from Ultra 
International Pvt Ltd. All other chemicals were of 
analytical grade. 
 
Preformulation studies 
The preformulation studies were carried out for API 
Ranitidine HCl. Visual examination of Ranitidne HCl 
powder was carried out by transferring 50 mg on to 
white paper, spreading and examining visually in any 
light. Melting point was determined using capillary 
melting point apparatus. The solubility was 
determined by the equilibrium solubility method.  An 
excess of the drug was placed in a solvent system and 
shaken at a constant temperature (30°C ± 2°C) over a 
period until equilibrium was obtained. In the present 
study, the solubility of Ranitidine HCl was tested in 
distilled water, phosphate buffers pH 6.8 and 0.1 N 
HCl at 30°C ± 0.2°C.  
 
Drug – Excipient compatibility: 
The drug excipient compatibility studies were 
conducted by analyzing FTIR spectra of pure 
Ranitidine HCl, a combination of Ranitidine HCl 
with excipients and blend of excipients kept in vials 
for periods of 4 weeks viz.,  25° C ± 2° C/ 60% RH 
±5% RH, accelerated stability storage conditions 
(40°C ± 2°C / 75% RH ± 5% RH)and 55°C ± 2°C. 
The samples were analysed after 30 days. Fourier 
transforms infrared (FTIR) spectra (4000‑400 
cm−1and resolution of 4 cm−1) of all the samples was 
measured by preparing dispersion in dry KBr using 
attenuated total reflectance FTIR spectrophotometer. 
The absorption maxima in the spectra obtained were 
compared, and the presence of additional peaks 
corresponding to the functional groups was noted. 
 
DSC Studies: 
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The heat characteristics of CBZ and drug‑polymer 
mixtures were analysed using a Shimadzu® 
Differential scanning calorimeter (DSC)‑60 
(Shimadzu, Kyoto, Japan). The behavior was studied 
by heating the samples (2 mg) from 25°C to 400°C at 
a heating rate of 10°C/min under nitrogen flow at 10 
cm3/min−1 using an empty aluminum pan as a point of 
reference. 
 
Preparation oral medicated jellies: 
For batches F1 to F3: Accurately weighed pectin 
(SS121) and trisodium citrate were mixed with 10% 
sucrose (taken from the total amount) and stirred into 
the water until the pectin is completely dissolved. 
Sucrose was triturated with the drug and was 
dispersed in dextrose syrup. This was added in the 
polymer solution. The mixture was stirred using an 
overhead stirrer (Remi Motors; type-RO122). The 
solution was heated till it reaches the desired brix. 
The brix was measured using handheld refractometer 
(Erma Inc.; Japan). Sodium benzoate was also 
dissolved in minimal quantity of water and added 
followed by mango flavour under continuous stirring. 
Citric acid solution was added to this under 
continuous stirring at 60°C to adjust the pH to 3.7 
using pH meter (EcoTestr pH 2 Waterproof Pocket 
Tester). These batches were then subjected to drying. 
For batches F4 and F5: Accurately weighed polymer 
powder pectin was mixed with 10% sucrose was 
dispersed in purified water containing of citric acid 
and trisodium citrate. Sucrose was triturated with the 
drug and was dispersed in dextrose syrup. The 
temperature was maintained at 60°C throughout 
preparation for both the mixtures. The dispersion was 
stirred using an overhead stirrer (Remi Motors; type-
RO122) for 20 min to facilitate hydration of gelling 
agent. Then syrup mix was added to the polymer 
solution. The solution was heated till it reaches the 
desired brix or the total solid content. The brix was 
measured using handheld refractometer (Erma Inc.; 
Japan).Sodium benzoate was also dissolved in 
minimal quantity of water and added followed by 
mango flavour under continuous stirring. Citric acid 
solution was added to this under continuous stirring 
at 60°C to adjust the pH to 3.7. These batches were 
subjected to variable brix and drying time. 
 
Evaluations of Oral medicated jellies:  
Pourability of the mixture: 
The jelly formulation mixture should be easily 
pourable in the moulds. The buffer salts (retarders) 
like trisodium citrate play an important role in this 
process.With the addition of these retarders the 
approaching of the pectin molecules during the hot 
phase is interfered sterically. They also raise the pH-
value before the acid addition, thus preventing pre-
gelation. The higher the buffer salt, i.e. retarder, 
concentration, the lower the setting temperature and 
the longer the setting time. This provides sufficient 
time for pouring and setting of the jelly. 
Physical appearance: 
Consistency and structure together make up the so-
called texture. Texture is the overall impression of 
the sensory feeling and describes especially the 
mouth feel of a product. The texture of the prepared 
medicated jellies was analysed visually.   
Stickiness and grittiness:  
Texture of the medicated jelly in terms of stickiness 
and grittiness had been evaluated by visual inspection 
of the product after mildly rubbing the jelly sample 
between two fingers. 
pH determination:  
The pH value of 5-6 is considered optimal for gelling 
and taste reason. The pH of prepared jellies was 
measured using a digital pH meter at room 
temperature (25°C ± 5°C). For this purpose, 0.5 g of 
jelly was dispersed in 50 mL of distilled water to 
make a 1% solution, and the pH was noted. 
 
Table 1: Fomualtion batches of Ranitidine Hydrochloride Oral medicated jellies. 
 
Ingredients (in %) F1 F2 F3 F4 F5 
Ranitidine HCl 1 1 1 1 1 
Pectin  1.3 1.5 4 2.2 2.5 
Trisodium citrate 3.3 3.3 2 0.4 0.4 
Citric acid - - - 0.37 0.37 
Sucrose  50 50 36 30 30 
Glucose syrup 30 30 47.5 52 52 
Citric acid solution 
50% 
1 ml 1.2 ml 1.4ml 0.8ml 1ml 
Sodium benzoate 0.01 0.01 0.01 0.01 0.01 
Water  22 22 20 30 30 
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Flavour 1ml 1ml 1ml 1ml 1ml 
In vitro Taste analysis:  
5 mL of pH 6.8 phosphate buffer (to simulate 
salivary pH and volume) was used to study the taste 
masking efficiency of jelly preparation. One jelly 
from optimised batch was placed in 50 mL beaker. 5 
ml of the buffer solution was then added and the 
beaker was allowed to stand for 60 sec and 120 sec, 
respectively. After the specified time, the buffer 
solution was filtered. The filtrates were analyzed for 
drug content by UV. The test was performed in 
triplicate 
 
Syneresis: 
Syneresis is the contraction of the gel upon storage 
and separation of water from the gel. It is more 
pronounced in the gels, where lower concentration of 
gelling agent is employed. It is one of the major 
problems associated with low acylated guar gum gels 
[24]. All the jellies were observed for signs of 
syneresis at room temp (25°C ± 5°C) and 8°C ± 
1°C.The formulations showing signs of syneresis 
were rejected and not considered for further studies. 
Percent drug content: 
Ranitidine HCl jellies were tested for their drug 
content. Twenty jellies were finely crushed to gel 
consistency; quantity of the gel equivalent to 50mg of 
Ranitidine HCl was accurately weighed and 
transferred to a 50ml volumetric flask. To the flask 
water was added and contents were mixed thoroughly 
and sonicated for 45minutes. The solution was made 
upto 50ml and filtered. Various dilutions of the 
solution were performed. The absorbance of the 
resulting solution was measured at 310nm using 
Shimadzu UV visible spectroscopy.  
 
Dissolution studies: 
The invitro dissolution study was performed by using 
a USP type 2 paddle apparatus at a rotational speed 
of 50rpm. 900ml of media was used as the 
dissolution medium and the temperature was 
maintained at 37⁰ C± 0.5⁰C. A 5ml aliquot was 
withdrawn from the dissolution apparatus at specified 
time intervals for one hour and the same volume was 
replaced with the fresh dissolution media. The 
samples were filtered through whatman filter paper. 
Absorbance of these solutions was measured at 
310nm in water by using Shimadzu UV visible 
spectroscopy. The drug release profile was 
calculated. 
 
Microbial studies: 
It is important to determine the microbial profile of 
jellies as they are contain pectin which is of natural 
origin and water which favors microbial growth. 
Microbial growth occurs due to improper 
maintenance and manufacturing conditions. The 
jellies were tested for E. coli, S. aureus and P. 
aeruginosa by culturing on pathogen specific 
mediums. 
 Requirements: 
The working area for conducting microbial 
experiments viz. Laminar air flow chamber was 
sterilized by first cleaning the working platform and 
side frame with 75% isopropyl alcohol (IPA), 
followed by UV treatment for 20- 25minutes and 
then blower was kept on for the next 10-15 minutes. 
All the glass apparatus used for conducting microbial 
experiments were sterilized in the autoclave 
(condition 121⁰Cand 15psi for 15minutes) followed 
by UV treatment for 20-25 minutes. The agar 
mediums and nutrient broth mediums used in these 
experiments were sterilized in autoclave (121⁰C and 
15psi for 15minutes).  
Preparation of sample stock solution: 
 1g jelly formulation was dissolved in saline solution 
and the volume was made up to 10ml with the saline 
solution. 
  
Test for E.coli using Mac Conkey agar: 
25ml of hot melted Mac Conkey agar medium was 
first poured in the sample and control petriplates and 
the medium was allowed to solidify in LAF chamber. 
After medium solidification, two nichrome loopful of 
stock solution of formulation was streaked in three 
sample petriplates. 
Control petriplates: 
Media control: 25ml of Mac Conkey agar medium 
was transferred in a petriplate. 
Diluent control: 25ml of Mac Conkey agar medium 
was transferred in a petriplate and allowed to solidify. 
Two nichrome loopful of saline solution (diluents) 
was den streaked on the medium. 
Positive control: 25ml of Mac Conkey agar medium 
was transferred in a petriplate and allowed to solidify. 
Two nichrome loopful of E. coli was streaked on the 
medium. 
Test for S.aureus: 
25ml of hot melted Vogel Johnson agar medium was 
first poured in the sample and control petriplates and 
the medium was allowed to solidify in LAF chamber. 
After medium solidification, two nichrome loopful of 
stock solution of formulation was streaked in three 
sample petriplates. 
Control petriplates: 
Media control: 25ml of Vogel Johnson agar medium 
was transferred in a petriplate. 
Diluent control: 25ml of Vogel Johnson agar medium 
was transferred in a petriplate and allowed to solidify. 
IAJPS 2017, 4 (06), 1746-1754         Melissa R Cardoz and Padmini Ravikumar        ISSN 2349-7750
 
 
w w w . i a j p s . c o m  
 
Page 1750 
Two nichrome loopful of saline solution (diluents) 
was den streaked on the medium. 
Positive control: 25ml of Vogel Johnson agar 
medium was transferred in a petriplate and allowed to 
solidify. Two nichrome loopful of S. aureus was 
streaked on the medium. 
Test for P. aeruginosa: 
25ml of hot melted Cetrimide agar medium was first 
poured in the sample and control petriplates and the 
medium was allowed to solidify in LAF chamber. 
After medium solidification, two nichrome loopful of 
stock solution of formulation was streaked in three 
sample petriplates. 
Control petriplates: 
Media control: 25ml of Cetrimide agar medium was 
transferred in a petriplate. 
Diluent control: 25ml of Cetrimide agar medium was 
transferred in a petriplate and allowed to solidify. 
Two nichrome loopful of saline solution (diluents) 
was den streaked on the medium. 
Positive control: 25ml of Cetrimide agar medium was 
transferred in a petriplate and allowed to solidify. 
Two nichrome loopful of P. aeruginosa was streaked 
on the medium. 
 
RESULTS AND DISCUSSION: 
Standardisation of drug  
5.1.1 Appearance and melting point:  The table 5.1 
shows the results for appearance or standardization of 
drug 
Table 2: Appearance and melting point 
Sr No Parameter  Results  
1 Appearance  Creamish white  
2 Melting point  142°C ±2°C 
 
 Solubility Studies:  
The table 5.2 shows the results for solubility studies 
in 0.1 N HCl, water and 6.8 pH phosphate buffer 
Table 3: Results of solubility studies 
Sr no solvent  Solubility  
1 0.1N HCl  Soluble 
2 Water Freely soluble  
3 pH 6.8  buffer Soluble 
 
Drug- excipient compatibility:  
Physical examination of individual drug‑excipient 
mixtures stored at 40°C and 75% RH was carried out 
for 45 days. The initial color of the drug‑excipient 
mixtures observed as white to brownish for pectin 
and all other excipients along with the drug showed 
white to off white color. No characteristic changes 
were observed in color or physical state for all the 
samples at 15, 30 and 45 days. Fourier transforms 
infrared spectra of the pure drug is shown in Figure 1. 
Characteristic peaks of pure Ranitidine 
Hydrochloride are given in table no 4. The peaks 
were in compliance to those of standard values. No 
additional peaks corresponding to functional groups 
were obtained. There were no significant deviations 
found between the peaks of drug and those of 
drug‑excipient mixtures that indicated the stability of 
the drug in the presence of all excipients. The FTIR 
spectra of Ranitidine HCl is shown in Figure 1  
 
 
Fig 1: FTIR spectra of Ranitidine HCl 
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Table 4: Wavelength and corresponding 
functional groups in FTIR spectra of Ranitidine 
HCl 
Wavelength  Functional group 
2500cm-1 N-H (in protonated tertiary amine) 
1610 cm-1 C=N stretching 
1460 cm-1 C-N 
 
DSC Studies: 
The DSC thermogram of pure drug demonstrated a 
sharp endothermic peak at 146.43°C corresponding to 
the melting point of the crystalline form of Ranitidine 
Hydrochloride. Whereas the thermograms of the 
mixtures of the drug using gelling agents and other 
excipients showed varying deviations in the 
characteristic peaks between 130°C and 150°C . This 
shifting of endothermic peaks to lower temperatures 
could be due to the formation partial drug-polymer 
complexes. The DSC thermogram of pure drug is 
shown in figure no. 2. 
 
 
Fig 2:  DSC thermogram of Ranitidine HCl 
 
Selection of optimized formulation 
Among the batches prepared batch F4 showed good 
pourability of mixture and gelling. The jelly formed 
had a firm and smooth texture. Hence this batch was 
selected as the optimized batch for further evaluation. 
The brix of the jelly was varied between 70– 80. Six 
batches were prepared with the following ⁰brix. 
 
Table 5:  Optimisation of Batch F4 at different 
⁰brix values 
Batch   ⁰Brix  
F4.1 70 
F4.2 72 
F4.3 74 
F4.4 76 
F4.5 78 
F4.6 80 
 
Physical appearance: 
The texture of the jellies prepared looked smooth and 
soft in appearance at brix 74°. At brix 80° the texture 
looked rough. Results of physical appearance are 
given in table no 7. 
 
Stickiness:  
All the jellies prepared showed stickiness. Hence the 
jellies were dried for 7hrs at 50⁰C. The stickiness was 
found to be reduced after drying. Results of stickiness 
before and after drying are given in table no 7. 
Table 6: Results of stickiness before and after 
drying 
Batch   Before drying  After drying  
F4.1 Very sticky  Sticky  
F4.2 Sticky  Sticky  
F4.3 Sticky  Less sticky  
F4.4 Sticky  Less sticky  
F4.5 Sticky  Less sticky  
F4.6 Sticky  Sticky  
 
pH of jellies :  
The pH of the jellies of the optimized batch was 
found out to be between the optimum range of 4.9- 
6.3. Results of pH of jellies are given in table no 7. 
 
Syneresis:  
There was no syneresis observed in the optimized 
batch at the specified temperature. 
Invitro taste analysis:  
There was no significant drug release observed 
during in vitro taste evaluation hence it can be 
correlated to taste feel. As insignificant drug was 
released, it is insufficient to impart bitterness.  
 
Table 7: Results of physical appearance, pH and 
invitro taste analysis. 
Batch   Physical 
appearance  
pH  % drug content 
(invitro taste 
analysis) 
F4.1 Very soft  5.89  3.40 
F4.2 Smooth and very 
soft  
5.74 1.34 
F4.3 Smooth and firm  5.01 1.12 
F4.4 Smooth  6.02 1.52 
F4.5 Smooth  5.53 3.35 
F4.6 Slightly rough  4.95 1.85 
 
Dissolution study:  
All the formulations of prepared oral medicated 
jellies were subjected to invitro release studies using 
dissolution apparatus in water. The release data 
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obtained for all the formulations are tabulated in table 
no and figure no shows plot of percent drug released 
as a function of time for different formulations 
Table  8: Invitro dissolution profile of Ranitidine HCl in water 
 
Time intervals 
(mins)  
F4.1  F4.2  F4.3  F4.4  F4.5  F4.6  
5  35.71  40.71  43.77  34.58  39.17  48.75  
10  50.45  62.76  62.01  64.26  56.63  62.81  
20  70.16  74.60  70.40  77.25  66.90  73.88  
30  73.56  81.52  74.62  83.42  73.39  76.20  
45  78.08  85.80  87.77  84.27  79.16  79.30  
60  80.50  87.80  92.20  90.47  87.63  84.71  
 
 
 
Fig 3:  Invitro dissolution profile of Ranitidine HCl 
 
Drug content:  
The drug content of the formulation F4.3 was found to be 92.75% . 
 
Microbial studies  
Test for E.coli on Mac Conkey agar: 
  
Table 9: Observed E. coli colonies in sample and control petriplates of formulation. 
Microbes No of E. coli colonies observed in 
sample pertiplates  
No of E. coli colonies observed in Control pertiplates  
 i ii Medium control Negative control Positive control 
F4.3 0 0 - - + 
 
Test for S. aureus on Vogel Johnsons agar:  
 
Table 10: Observed S. aureus colonies in sample and control petriplates of formulation. 
 
Microbes No of S. aureus colonies observed 
in sample pertiplates  
No of E. coli colonies observed in Control pertiplates  
 i ii Medium control Negative control Positive control 
F4.3 0 0 - - + 
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Test for P. aeruginosa on Cetrimide agar:  
 
Table 11: Observed P. aeruginosa colonies in sample and control petriplates of formulation. 
 
Microbes No of P. aeruginosa colonies 
observed in sample pertiplates  
No of E. coli colonies observed in Control pertiplates  
 i ii Medium control Negative control Positive control 
F4.3 0 0 - - + 
 
CONCLUSION: 
In the present work oral medicated jellies of 
Ranitidine HCl were formulated by matrix 
entrapment technique and addition of sweeteners and 
flavors. The preformulation studies of solubility 
showed that Ranitidine HCl was freely soluble in 
water, pH 6.8 phosphate buffer and 0.1N HCl. DSC 
and FTIR studies showed that there was no apparent 
interaction between the excipients and the drug. 
Formulation batches prepared were checked for 
gelling and texture. Batch F4 was selected for further 
optimization by varying total solid content (brix) in 
the jelly formulation. All the batches showed pH 
between 4- 6. The optimized batch showed good 
texture with more than 50% drug release in 15mins. 
The invitro taste analysis was carried out which 
showed minimal amount of drug was released in 
simulated saliva proving that the bitter taste of the 
drug would not be sensed by the taste buds in the 
mouth. The dosage form prepared did not show 
syneresis at room temperature. Hence we conclude 
that a novel taste masking formulation of Ranitidine 
HCl has been developed for pediatric, geriatric and 
dysphagic patients. 
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